Prognostic impact of the level of neck metastasis in oral cancer patients

Hugo Fontan Köhler¹, Luiz Paulo Kowalski²

Abstract

Neck staging in oral cancer depends on the number of compromised nodes, their size and side of occurrence.

Objective: This paper aims to evaluate risk factors for metastatic nodes in levels IV/V and their prognostic impact on patients with oral carcinoma.

Method: Retrospective study. Inclusion criteria: pathologist’s diagnosis of squamous cell carcinoma, primary tumor in the lower oral cavity, no extension into extraoral sites, no previous treatment, synchronous neck dissection and presence of metastatic nodes. Risk factors for metastasis were evaluated through logistic regression and disease-specific survival and recurrence by survival analysis. Classificatory analysis was performed through recursive partitioning.

Results: 307 patients met the inclusion criteria. Univariate logistic regression identified pN stage, vascular invasion, and multiple metastatic nodes as risk factors for metastases in levels IV/V. Multivariate analysis found vascular invasion and multiple metastatic nodes were significant. Survival analysis revealed pT, pN, neural infiltration, vascular invasion, number of metastatic nodes, metastases in levels IV/V, and node ratio were significant factors. In multivariate survival analysis, pT, pN, vascular invasion and metastases in levels IV/V were significant. Classificatory analysis showed that pN is non-significant in patients with level IV/V metastases.

Conclusion: The occurrence of metastases in levels IV/V was significant for disease-specific survival.

Keywords: head and neck neoplasms, mouth neoplasms, neck dissection, prognosis, survival rate.
INTRODUCTION

Squamous cell carcinomas (SCC) of the oral cavity are categorized in different stages to reflect prognostic factors and determine the most adequate standard course of therapy. Tumor staging looks into the characteristics of the primary tumor along with node and systemic metastases. Neck lymph nodes are usually the first site affected by metastases in patients with high digestive tract SCC. Presence of metastasis is one of the most relevant prognostic factors for patients with oral SCC.

Neck staging in patients with high digestive tract tumors is standard for most primary tumor sites and is based on the number of metastatic nodes, the size of the largest node, and the side of the involved node in relation to the primary tumor. Depending on the combination of these factors, patients are assigned to one of six stages. However, this system does not cover all prognostic factors known to be significant, such as the presence of extracapsular tumor extension or lymph node density. The staging system's prognostic role has also been criticized due to the limitations it poses mainly in patients submitted to adjuvant therapy, for whom its discriminatory power is significantly diminished.

Neck lymph nodes are grouped in levels related to well defined anatomic regions of the neck. Tumor involvement of neck nodes does not occur randomly. Patterns of involvement can be predicted as a function of the primary tumor site, as described in the literature, and used to aid in selective neck dissection (ND) procedures. Node metastases in oral SCC occur initially on levels I to III, and that is the rationale for selective ND involving these levels and, further on, they reach levels IV and V.

This paper aimed to analyze the risk factors for the presence of node metastasis on levels IV/V and their impact on the disease-specific survival of patients with oral carcinoma.

METHOD

This study enrolled patients treated consecutively at one institution from January 1985 to December 2005. Inclusion criteria: confirmed diagnosis of SCC by histopathology testing, primary tumor located in the lower oral cavity, no tumor extension onto extraoral sites or onto the oropharynx, no previous treatment, synchronous neck dissection, and presence of metastatic nodes on surgical specimen. Exclusion criteria: patients with tumors other than SCC as confirmed by histopathology testing, tumors extending to the skin, oropharynx or other sites, patients submitted to previous treatment, primary tumor surgery without neck dissection, patients without metastatic nodes on pathology testing (pNO), patients receiving radiotherapy/chemoradiotherapy, and patients with diagnosed systemic metastasis. The staging of all patients was updated as per the standard procedure described in 2009. This study was approved by the Institutional Research Ethics Committee (permit nº 571/2007).

Statistical analysis was performed on software program Stata 12.1 for MacOs. Categorical variables were described by their frequencies of occurrence, whereas continuous variables were described in terms of their mean values and standard deviations (SD). Logistic regression was used to correlate risk factors to the presence of level IV/V metastases. Survival analysis was done based on the Kaplan-Meier and Nelson-Aalen curves, combined to the Cox model. Classification analysis was performed by recursive partitioning, with divisions with a minimum of five cases and a cutoff value of 0.05. Percentages were rounded up to two decimal fractions and continuous variables to three decimal fractions. P-values equal to or smaller than 0.05 were deemed statistically significant.

RESULTS

Three-hundred and seven consecutive patients were included in this study. The sample had 266 males (86.64%) and 41 females (13.36%). Age at diagnosis ranged between 22 and 85 years (mean: 56.13 years; SD: 10.50 years). Primary tumor sites can be seen on Table 1. Primary tumors were staged as pT1 in nine patients (2.93%), pT2 in 112 patients (34.68%), pT3 in 99 patients (32.25%) and pT4a in 87 patients (28.34%). Neck dissection was performed in all patients simultaneously to primary tumor ablation. ND on levels I-IV (supraomohyoid extended to level IV) was performed on 177 patients (57.65%), modified radical ND in 85 patients (27.69%), and classic radical ND in 45 patients (14.66%). Ninety-three patients (30.29%) underwent bilateral ND. The number of retrieved nodes on ipsilateral dissections ranged...
Table 1. Primary tumor sites of the patients included in this series.

| Primary site              | Number of patients | Percent  |
|---------------------------|--------------------|----------|
| Oral tongue               | 132                | 43.00%   |
| Mouth floor               | 63                 | 20.52%   |
| Retromolar trigone        | 85                 | 27.69%   |
| Lower gum ridge           | 23                 | 7.49%    |
| Cheek mucosa              | 4                  | 1.30%    |
| Total                     | 307                | 100%     |

Table 2. Distribution of patients as a function of neck clinical and pathology staging.

| pN1 | pN2a | pN2b | pN2c | pN3   | Total |
|-----|------|------|------|-------|-------|
| cN0 | 42   | 3    | 44   | 7     | 96    |
| cN1 | 39   | 2    | 53   | 14    | 108   |
| cN2a| 4    | 1    | 17   | 1     | 25    |
| cN2b| 8    | 0    | 31   | 8     | 48    |
| cN2c| 2    | 0    | 1    | 12    | 15    |
| cN3 | 1    | 1    | 8    | 4     | 15    |
| Total| 96  | 7    | 154  | 46    | 307   |

Table 3. Distribution of patients with level IV/V metastasis as a function of neck pathology staging.

| cN  | Number of patients | Level IV/V metastasis (%) | pN  | Number of patients | Level IV/V metastasis (%) |
|-----|--------------------|---------------------------|-----|--------------------|---------------------------|
| cN0 | 96                 | 7 (7.29)                  | -   | -                  | -                         |
| cN1 | 108                | 10 (9.25)                 | pN1 | 96                 | 2 (2.08)                  |
| cN2a| 25                 | 3 (12.00)                 | pN2a| 6                  | 1 (16.67)                 |
| cN2b| 48                 | 9 (18.75)                 | pN2b| 132                | 22 (16.67)                |
| cN2c| 15                 | 1 (6.67)                  | pN2c| 37                 | 9 (24.32)                 |
| cN3 | 15                 | 4 (26.67)                 | pN3 | 4                  | 0 (0)                     |

Table 4. Multivariate analysis by logistic regression of the risk factor for level IV/V metastasis.

| Variable       | Odds ratio | 95% CI            | p-value |
|----------------|------------|-------------------|---------|
| Vascular invasion | 3.877     | 1.032-14.574     | 0.045   |
| Involved nodes  | 1.484      | 1.287-1.710      | < 0.001 |

CI: Confidence Interval.

Univariate survival analysis revealed that pT and pN stages, vascular invasion, neural infiltration, number of metastatic nodes, node ratio, and presence of metastatic nodes on levels IV and V were statistically significant (Table 5). These variables were included in a stepwise approach to multivariate analysis, which revealed that pT stage, pN stage, vascular invasion, and node metastases on levels IV and V were statistically significant (Table 6). Patients with metastasis on levels IV and V had worse disease-specific survival than those with metastatic disease limited to levels I to III (Figure 1).

Table 5. Significant variables identified in disease-specific survival univariate analysis.

| Variable        | Relative risk | 95% CI           | p-value |
|-----------------|---------------|------------------|---------|
| pT stage        | 1.618         | 1.342-1.950      | < 0.001 |
| pN stage        | 1.228         | 1.066-1.414      | 0.004   |
| Level IV/V metastasis | 2.624 | 1.717-4.008      | < 0.001 |
| Vascular invasion | 1.695     | 1.142-2.518      | 0.009   |
| Neural infiltration | 1.613 | 1.165-2.232      | 0.004   |
| Number of metastatic nodes | 1.037 | 1.013-1.061 | 0.002   |
| Node ratio      | 5.278         | 1.644-16.949     | 0.005   |

CI: Confidence Interval.

Patients with metastatic nodes on levels IV/V were at significantly higher risk for systemic metastasis than those without neoplastic involvement in these levels (relative risk (RR): 5.182; 95% confiden-
Table 6. Disease-specific survival multivariate analysis.

| Variable                  | Relative risk | 95% CI          | p-value |
|---------------------------|---------------|-----------------|---------|
| pT stage                  | 1.618         | 1.326-1.975     | < 0.001 |
| Level 4/5 metastasis      | 1.962         | 1.249-3.080     | < 0.001 |
| Vascular invasion         | 1.458         | 1.087-2.191     | 0.037   |
| pN stage                  | 1.447         | 1.041-2.011     | 0.028   |

CI: Confidence Interval.

Analysis by recursive partitioning including the presence of neck metastasis on levels IV/V and pN stage revealed that the latter was not significant for patients with metastasis on levels IV/V, although it was significant for patients with neoplastic involvement on levels I/III (Figure 4). When patients were stratified as a function of the presence of metastasis on levels IV/V, prognostic factors varied between groups and it was not possible to determine which related to the group with neoplastic involvement on levels IV/V (Table 7).
DISCUSSION

Cancer patient staging is done to estimate prognosis and help define the need for adjuvant therapy in surgery patients. For patients with oral SCC, the pN stage is highly significant for disease-specific survival and should be used to stratify these patients in trials due to its relevant prognostic impact. The extension of selective ND in oral SCC patients to include levels IV and V has been discussed in the literature. A paper comparing neck relapse rates in patients submitted to selective and radical ND revealed similar results for both approaches, and the authors concluded that the removal of nodes on levels I to III was sufficient. No cases of isolated level IV involvement were seen in 81 oral SCC patients submitted to selective ND, thus indicating to the authors that node removal was not necessary in cN0 patients. However, the authors stressed that the metastasis distribution pattern is less predictable in cN0 patients. The incidence rate of metastasis on levels IV/V was 2.91% of patients submitted to selective ND revealed low relapse rates on level V nodes. In such series it was evident that the presence of extracapsular extension and multiple metastatic nodes were the most relevant prognostic factors in the neck. A retrospective series with pN2 patients showed that the presence of node metastasis on levels IV/V was a significant prognostic factor for patient survival. In our series this prognostic factor was also assessed for pN1 patients and proved to be statistically significant for them as well. Additionally, the risk factors for the presence of level V metastasis were related to pathological characteristics available only on the final pathology tests. The impact of the presence of metastasis on the survival of these patients is a topic that requires more discussion in the literature. An analysis of patients submitted to selective ND revealed low relapse rates on level V nodes. In such series it was evident that the presence of extracapsular extension and multiple metastatic nodes were the most relevant prognostic factors in the neck. A retrospective series with pN2 patients showed that the presence of node metastasis on levels IV/V was a significant prognostic factor for patient survival. In our series this prognostic factor was also assessed for pN1 patients and proved to be statistically significant for them as well. Additionally, the presence of level IV/V metastasis was found to overwhelm all other parameters related to the N stage in terms of prognostic status in a classificatory analysis. Therefore, this seems to be the main prognostic trait for patients with node involvement.

CONCLUSION

The occurrence of metastasis on levels IV/V correlates to the pathological characteristics of the primary tumor. Isolated occurrence of level IV/V metastasis is rare. Neoplastic involvement in levels

---

**Table 7.** Survival multivariate analysis after patients were stratified according to the presence or absence of level IV/V metastatic nodes.

| Variable          | No level IV/V metastasis RR (95% CI), p-value | Present level IV/V metastasis RR (95% CI), p-value |
|-------------------|-----------------------------------------------|---------------------------------------------------|
| pT stage          | 1.654 (1.332-2.053), < 0.001                  | 1.200 (0.555-2.591), 0.642                         |
| pN stage          | 1.325 (1.089-1.821), 0.015                    | 0.870 (0.402-1.887), 0.725                         |
| Vascular invasion | 1.583 (1.036-2.418), 0.034                    | 0.872 (0.168-4.532), 0.870                         |

RR: Relative Risk; CI: Confidence Interval.
IV and V is in itself an important prognostic factor for patients with oral squamous cell carcinoma and impacts disease-specific survival, but does not affect neck relapse rates. This fact poses relevant impact upon the occurrence of systemic metastasis and must be taken into account in the indication of adjuvant therapy and, possibly, in the staging of these tumors.

REFERENCES

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. New York: Springer; 2009.
2. Grandi C, Alloisio M, Moglia D, Podrecca S, Sala L, Salvatori P, et al. Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutics implications. Head Neck Surg. 1985;8(2):67-73.
3. Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 2005;55(4):242-58.
4. Köhler HF, Kowalski LP. How many nodes are needed to stage a neck? A critical appraisal. Eur Arch Otolaryngol. 2010;267(5):785-92.
5. Gómez L, Carlsson DL, Boyle JO, Kraus DH, Shah JP, Shaha AR, et al. Lymph node density is a significant predictor of outcome in patients with oral cancer. Cancer. 2009;115(24):5700-10.
6. Shingaki S, Takada M, Sasai K, Kobayashi T, Nomura T, et al. Impact of node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg. 2003;185(3):278-84.
7. Shah JP, Candela FC, Poddar AR. The patterns of cervical lymph node metastases from squamous cell carcinoma of the oral cavity. Cancer. 1999;86(1):109-15.
8. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous cell carcinoma. Brazilian Head and Neck Cancer Study Group. Am J Surg. 1998;176(5):422-7.
9. Le Torneau C, Velten M, Jung GM, Bronner G, Flesch H, Borel C. Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases. Head Neck. 2005;27(9):801-8.
10. Kowalski LP, Carvalho AL. Feasibility of supraomohyoid neck dissection in N1 and N2a oral cancer patients. Head Neck. 2002;24(10):921-4.
11. Mishra P, Sharma AK. A 3-year study of supraomohyoid neck dissection and modified radical neck dissection type I in oral cancer: with special reference to involvement of level IV node metastasis. Eur Arch Otolaryngol. 2010;267(6):935-8.
12. Naiboğlu B, Karapinar U, Agrawal A, Schuller DE, Ozer E. When to manage level V in head and neck carcinoma? Laryngoscope. 2011;121(5):545-7.
13. De Zinis IO, Bolzoni A, Piazza C, Nicolai P. Prevalence and localization of nodal metastases in squamous cell carcinoma of the oral cavity: role and extension of neck dissection. Eur Arch Otolaryngol. 2006;263(12):1151-5.
14. Bajwa SM, McMillan R, Khattak O, Thomas M, Krishnan OP, Webster K. Neck recurrence after level I-IV or I-III selective neck dissection in the management of the clinically N0 neck in patients with oral squamous cell carcinoma. Head Neck. 2011;33(3):403-6.
15. Lim YC, Koo BS, Lee JS, Choi EC. Level V lymph node dissection in oral and oropharyngeal carcinoma patients with clinically node-positive neck: is it absolutely necessary? Laryngoscope. 2006;116(7):1252-5.
16. Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. Arch Otolaryngol Head Neck Surg. 1994;120(7):699-702.
17. Ambrosch P, Kron M, Pradier O, Steiner W. Efficacy of selective neck dissection: a review of 503 cases of elective and therapeutic treatment of the neck in squamous cell carcinoma of the upper aerodigestive tract. Otolaryngol Head Neck Surg. 2011;145(2):180-7.
18. Liao CT, Huang SF, Chen HI, Kang CJ, Lin CY, Fan KH, et al. Outcome analysis of patients with pN2 oral cavity cancer. Ann Surg Oncol. 2010;17(4):1118-26.